The U.S. Food and Drug Administration allowed the expanded use of Sarepta Therapeutics' gene therapy for patients with ...
The U.S. Food and Drug Administration has expanded the approval of Sarepta Therapeutics' Elevidys (delandistrogene ...
On the heels of a Phase III flop for Pfizer’s Duchenne muscular dystrophy gene therapy candidate, the FDA will decide whether ...
The U.S. Food and Drug Administration has expanded its previous approval for Sarepta Therapeutics’ gene therapy to treat ...
Shares of Sarepta SRPT rose nearly 34% in after-market trading on Thursday after it announced that the FDA approved the expanded use of its Duchenne muscular dystrophy (DMD) gene therapy Elevidys.
The stock price of Sarepta Therapeutics, a biotech company focused on the discovery and development of RNA-targeted ...
The US Food and Drug Administration has given the green light for the first gene therapy that treats a rare form of muscular dystrophy to be used in most people who have the disease and a certain ...
Shares of Sarepta SRPT rose nearly 34% in after-market trading on Thursday after it announced that the FDA approved the expanded use of its Duchenne muscular dystrophy (DMD) gene therapy Elevidys.
The U.S. Food and Drug Administration has given the green light for the first gene therapy that treats a rare form of muscular dystrophy to be used in most people who have the disease and a ...
The Muscular Dystrophy Association trusts the decision of the FDA, which weighs the risks and benefits of the drug The Muscular Dystrophy Association trusts the decision of the FDA, which weighs ...